|
|
 |
 | Medical News Releases > Faculty Experts at Washington University in St. Louis >
Head of the Department of Neurology
Expertise: Alzheimer's disease, dementia, neurology, molecular biology, monoclonal antibodies, amyloid plaques, perinatal stroke
Bio:
 |
| Holtzman |
Holtzman is known as one of the leading experts in researching the underlying mechanisms that lead to Alzheimer's disease in an effort to improve diagnosis and treatment. In addition to seeing patients at the Alzheimer's Disease Research Center and the Memory Diagnostic Center, Holtzman leads a research team working with animal models of Alzheimer's. The group has been instrumental in showing how dangerous amounts of a protein called amyloid-beta (Abeta) begin to accumulate in the brain many years before symptoms arise. These basic science investigations have evolved over the years and are beginning to bridge the gap into the clinical arena.
Education:
-
M.D. at Northwestern University
-
B.S. in Medical Education at Northwestern University
| News Stories & Tip Sheets: |
Showing Stories 1 through 5 of 15.
- Show More |
|
More benefits of sleep
Sleep loss linked to increase in Alzheimer's plaques
Sept. 24,
2009 -- Chronic sleep deprivation in a mouse model of Alzheimer's disease makes Alzheimer's brain plaques appear earlier and more often, researchers at the School of Medicine report online this week in Science Express.
|
Early indicator for Alzheimer's
Brain damage found in cognitively normal people with Alzheimer's marker
March 10,
2009 -- Researchers at the School of Medicine have linked a potential indicator of Alzheimer's disease to brain damage in humans with no signs of mental impairment. Although their cognitive and neurological assessments were normal, study participants with lower levels of a substance known as amyloid beta 42 (A-beta 42) in their cerebrospinal fluid (CSF) had reduced whole brain volumes, suggesting that Alzheimer's changes might already be damaging their brains.
|
High honors for WUSM scientists
Gordon, Holtzman elected to Institute of Medicine
Oct. 13,
2008 -- Two faculty members at the School of Medicine have been elected to the Institute of Medicine of the National Academy of Sciences, one of the highest honors medical scientists in the United States can receive. Jeffrey Gordon and David Holtzman were recognized for their major contributions to the advancement of the medical sciences, health care and public health and commitment to service.
|
Tracking biomarkers
Washington University in St. Louis and AstraZeneca announce Alzheimer's research collaboration
April 17,
2008 -- The School of Medicine and the pharmaceutical company AstraZeneca (NYSE:AZN) have announced a research collaboration that aims to develop new and improved ways to diagnose and treat Alzheimer's disease. The major focus of the alliance will be biomarkers, characteristic changes in the brain and spinal fluid that physicians can use to diagnose Alzheimer's disease and track its response to treatment.
|
Reducing plaque
Altering brain's lipid metabolism reduces Alzheimer's plaques in mice
Jan. 17,
2008 -- Increasing levels of a protein that helps the brain use cholesterol may slow the development of Alzheimer's disease changes in the brain, according to researchers studying a mouse model of the disease at the School of Medicine.
|
Showing Stories 1 through 5 of 15.
- Show More |
|
David Holtzman: Attacking Alzheimer's With a New Test for Amyloid Beta
U.S. News & World Report online
July 1,
2009 -- WUSTL neuroscientist David Holtzman and colleagues have devised a test that shows whether an experimental medication has a chance of working in Alzheimer's patients.
|
Alzheimer's Gene Slows Brain's Ability To Export Toxic Protein
ScienceDaily.com
Nov. 14,
2008 -- People who carry two copies of a particular gene have roughly eight to 10 times the risk of getting Alzheimer's disease than people who do not. WUSTL neuroscientist David Holtzman and graduate student Mary Beth Finn, were among the group of scientists that conducted research for this study.
|
Funding for Alzheimer's research is key, scientists say
Kansas City Star
and 17 others
July 5,
2006 -- Scientists who study Alzheimer's disease say they are on the brink of finding treatments to slow or stop it.
A few weeks ago, Congress voted to reduce funding for research on Alzheimer's disease.
WUSTL scientists commenting are neurology professor Anne Fagan Niven, neurology professor and chair David Holtzman, and Tom Meuser, director of education and rural outreach at WUSTL's Alzheimer's Disease Research Center.
|
Additional Background: Holtzman's research focuses on the underlying mechanisms of cell death and dysfunction in Alzheimer's disease and in perinatal stroke (strokes that occur just before, during or immediately after birth). His research has helped explain how plaques form in the brains of Alzheimer's patients. That process appears to begin decades before symptoms develop. Holtzman currently is examining the role of a monoclonal antibody called m266 in degrading these plaques, and he has found that the antibody has potential for use as a blood test for early diagnosis of Alzheimer's disease and as a therapeutic target for treatment. His research on perinatal stroke also has revealed novel therapeutic targets, and Holtzman now is exploring the use of drugs such as minocycline for limiting or preventing damage from perinatal stroke.
Affiliated with Barnes-Jewish Hospital and St. Louis Children's Hospital, members of BJC HealthCare.
Please contact us and let us know how we can assist you.
Technical problems with this Web site? Email questions or comments.
Please review the WUSTL News & Information copyright/privacy policy.
| |
|
| | |
|
Show More Clips
Print ready page